| Drug / Therapy | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T |
| Indication | — |
| Decision Type | Phase 1 |
| Trial Phase | Phase 1 |
| ClinicalTrials.gov | NCT04422912 |
Cabaletta Bio (CABA) operates in the Immunology sector. The current BTS Score is 48 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 1 date for A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T by Cabaletta Bio (CABA) is scheduled for January 1, 2029. This is the target date for the FDA to make a decision on this application.
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T is being developed by Cabaletta Bio for the treatment of its target indication. It is currently in Phase 1 clinical trials.
If A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T receives FDA approval, Cabaletta Bio (CABA) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for CABA on DilutionWatch at dilutionwatch.com/stock/CABA.html.
You can view the full BiotechSigns company profile for Cabaletta Bio (CABA) at biotechsign.com/app/company/CABA, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.